What Are the Next Moves When Checkpoint Inhibitors Fail?

Posted by Vikas Verma on Mar 16, 2018 8:00:00 AM

Marie Yurkovich and Malik Kaman co-authored this blog post with Vikas Verma.

Antibodies that target immune checkpoints, like those against programmed cell death-1 (PD-1) or its ligand (PD-L1), have rapidly changed the oncology treatment landscape for multiple tumor types including melanoma, bladder cancer and non-small-cell lung cancer (NSCLC). Opdivo and Keytruda, the flagbearers for anti-PD-1 therapy, have collective sales of more than $8 billion alongside a presence in more than six oncology indications.

Read More